Hoth Therapeutics, Inc. Common Stock (HOTH) Stock Price

HOTHStock
$0.53−69.63%52W
Market Cap—
P/E—
PEG Ratio—
Div yield—
Beta0.87

HOTH Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-16.94%
Price vs S&P 500 (4W)-28.43%
VGM Score30.80

HOTH Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q4 2025-$0.10-$0.16-60.00%(-$0.06)
Q3 2025-$0.07-$0.30-328.57%(-$0.23)
Q2 2025-$0.14-$0.17-21.43%(-$0.03)
Q1 2025-$0.34-$0.27+20.59%(+$0.07)

HOTH Analyst Recommendations

Feb 2026
Mar 2026
Apr 2026
May 2026
4.14
4.14
4.14
4.14

Industry Peers — Pharmaceuticals(574)

SymbolValue ScoreGrowth ScoreMomentum ScoreP/S Ratio (TTM)Revenue Growth TTM (YoY)Gross Margin (TTM)EPS Growth (5Y)Price
HOTHHoth Therapeutics, Inc. Common Stock
——D————$0.53
LLYEli Lilly & Co.DBA14.9x49.6%83.4%27.6%$1257.03
JNJJohnson & JohnsonDCB6.2x7.8%67.7%14.9%$255.56
ABBVABBVIE INC.DCA7.8x10.4%72.8%-2.9%$285.42
MRKMerck & Co., Inc.DCA5.4x4.6%77.3%21.2%$145.95
NVSNovartis AGCCB4.9x3.3%75.0%15.3%$150.62
AZNAstraZeneca PLCCBB4.3x8.6%81.3%21.9%$165.41
ABTAbbott LaboratoriesCCB3.9x8.1%56.8%8.2%$104.89
NVONovo-Nordisk A/SBCC3.5x5.6%80.7%20.7%$38.83
PFEPfizer Inc.CDA2.6x-0.2%74.7%-3.5%$29.58
VRTXVertex Pharmaceuticals IncDCB10.1x10.2%86.0%8.3%$499.74

About Hoth Therapeutics, Inc. Common Stock

Hoth Therapeutics is a clinical-stage biopharmaceutical company developing targeted therapies across oncology, immunology, neurology, and dermatology. Its pipeline includes treatments for cancer treatment side effects (HT-001), mast cell cancers and anaphylaxis (HT-KIT), Alzheimer's disease (HT-ALZ), atopic dermatitis (BioLexa), asthma and allergies (HT-004), and obesity (HT-VA). The company focuses on areas with significant unmet medical needs.